Souvie Biodelivery
Souvie Biodelivery: Pioneering nanotechnology for innovative drug delivery solutions.
Founded
2018Souvie Biodelivery: Pioneering nanotechnology for innovative drug delivery solutions.
Founded with a mission to revolutionize drug delivery, Souvie Biodelivery leverages nanotechnology to create advanced drug delivery platforms. The company focuses on developing engineered exosomes for tissue and site-specific active pharmaceutical ingredient (API) delivery. Their innovative solutions aim to enhance biocompatibility, reduce immunogenicity, and protect APIs from degradation, thereby increasing specificity and efficacy to minimize adverse drug reactions. Souvie Biodelivery targets niche markets within the pharmaceutical industry, aiming to set new standards in therapeutic delivery.
Souvie Biodelivery has garnered attention from notable investors and industry experts due to its pioneering approach in nanotechnology. The company has achieved significant milestones, including the successful patenting of its novel drug delivery platforms. Its impact is evident in the potential to transform how drugs are administered, offering safer and more effective treatments. Through its cutting-edge technology, Souvie Biodelivery is poised to make substantial contributions to the field of pharmaceutical sciences and patient care.
Companies similar to Souvie Biodelivery include Nanotransfer, Leonardo Biosystems, Nano PharmaSolutions and Tiny Cargo.
Souvie Biodelivery was founded in 2018.
Souvie Biodelivery's headquarters is located in Tucson, AZ, US.
Souvie Biodelivery's most recent funding round was for $225k (USD) in February 2021.
As of Feb 3, 2021, Souvie Biodelivery has disclosed funding of $225k (USD). Undisclosed round amounts are excluded.
Souvie Biodelivery has 1 employee as of Feb 4, 2024.
Tiny Cargo
tinycargo.com
